Browsing Tag
TRITON3
2 posts
Rubraca beats docetaxel in TRITON3: FDA clears early-line prostate cancer use for Tolmar
Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.
Can Rubraca really replace docetaxel in prostate cancer? FDA just said yes
Rubraca becomes first PARP inhibitor approved before chemo in BRCA+ prostate cancer. Find out how TRITON3 data is reshaping treatment strategy.